Prevention of recurrent fetal growth restriction

Obstetrics and Gynecology

Volumn 110, Issue 4, 2007, Pages 904-912

  Berghella, Vincenzo ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ANTIPHOSPHOLIPID SYNDROME; CALORIC INTAKE; CHEMOPROPHYLAXIS; CHRONOTHERAPY; CLINICAL TRIAL; DIET SUPPLEMENTATION; ECHOGRAPHY; FETUS MONITORING; FIRST TRIMESTER PREGNANCY; HEART INFARCTION; HUMAN; HYPERTENSION; INTRAUTERINE GROWTH RETARDATION; LOW DRUG DOSE; MALARIA; MALARIA CONTROL; MOTHER; NUTRITIONAL DEFICIENCY; OBSTETRIC CARE; PREECLAMPSIA; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; PROPHYLAXIS; PROTEIN RESTRICTION; RECURRENT DISEASE; REPRODUCTION; REVIEW; RISK REDUCTION; SMOKING CESSATION; THROMBOPHILIA; TREATMENT CONTRAINDICATION; TREATMENT PLANNING; VITAMIN SUPPLEMENTATION;

FEMALE; FETAL GROWTH RETARDATION; HUMANS; PREGNANCY; RECURRENCE; RISK FACTORS;

EID: 34848909862     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000267203.55718.aa     Document Type: Review

References (45)

1. Patterson RM, Gibbs CE, Wood R. Birth weight percentile and perinatal outcome: recurrence of intrauterine growth retardation. Obstet Gynecol 1986;68:464-8.
2. American College of Obstetrics and Gynecology. Intrauterine growth restriction. ACOG Practice Bulletin 12. Washington, DC: ACOG; 2000.
3. Resnik R, Creasy RK. Intrauterine growth restriction. In: Creasy RK, Resnik R, Iams JD, editors. Maternal-fetal medicine: principles and practice. 5th edition. Philadelphia (PA): Saunders; 2004.
4. Wilkins-Haug L, Quade B, Morton CC. Confined placental mosaicism as a risk factor among newborns with fetal growth restriction. Prenat Diagn 2006;26:428-32.
5. Zhu B-P, Rolfs RT, Nangle BE, Horan JM. Effect of the interval between pregnancies on perinatal outcomes. N Engl J Med 1999;340:589-94.
6. Lumley J, Oliver SS, Chamberlain C, Oakley L. Interventions for promoting smoking cessation during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
7. Crowther CA, Verkuyl DA, Neilson JP, Bannerman C, Ashurst HM. The effects of hospitalization for rest on fetal growth, neonatal morbidity and length of gestation in twin pregnancy. Br J Obstet Gynaecol 1990;97:872-7.
8. Kafatos AG, Vlachonikolis IG, Codrington CA. Nutrition during pregnancy: the effects of an educational intervention program in Greece. Am J Clin Nutr 1989;50:970-9.
9. Khoury J, Henriksen T, Christophersen B, Tonstad S. Effect of a cholesterol-lowering diet on maternal, cord, and neonatal lipids, and pregnancy outcome: a randomized clinical trial. Am J Obstet Gynecol 2005;193:1292-301.
10. Steegers EA, Van Lakwijk HP, Jongsma HW, Fast JH, De Boo T, Eskes TK, et al. (Patho)physiological implications of chronic dietary sodium restriction during pregnancy; a longitudinal prospective randomized study. Br J Obstet Gynaecol 1991;98:980-7.
11. Mahomed K. Iron supplementation in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006, Oxford: Update Software.
12. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems (Cochrane Review). In: The Cochrane Library, Issue 3, 2006. Oxford: Update Software.
13. Makrides M, Crowther CA. Magnesium supplementation in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
14. Mahomed K. Zinc supplementation in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
15. Mahomed K, Gulmezoglu AM. Vitamin D supplementation in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
16. Neilson JP. Ultrasound for fetal assessment in early pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
17. Abalos E, Duley L, Steyn DW, Henderson-Smart DJ. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy (Cochrane Review). In: The Cochrane Library, Issue 3, 2006. Oxford: Update Software.
18. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? [published erratum appears in Lancet 2005;365:656]. Lancet 2004;364:1684-9.
19. Kramer MS, Kakuma R. Energy and protein intake in pregnancy (Cochrane Review). In: The Cochrane Library, Issue 4, 2003. Oxford: Update Software.
20. Bulstra-Ramakers MT, Huisjes HJ, Visser GH. The effects of 3g eicosapentaenoic acid daily on recurrence of intrauterine growth retardation and pregnancy induced hypertension. Br J Obstet Gynaecol 1995;102:123-6.
21. Onwude JL, Lilford RJ, Hjartardottir H, Staines A, Tuffnell D. A randomised double blind placebo controlled trial of fish oil in high risk pregnancy. Br J Obstet Gynaecol 1995;102:95-100.
22. Olsen SF, Secher NJ, Tabor A, Weber T, Walker JJ, Gluud C. Randomised clinical trials of fish oil supplementation in high risk pregnancies. BJOG 2000:107;382-95.
23. Knight M, Duley L, Henderson-Smart DJ, King JF. Antiplatelet agents for preventing and treating pre-eclampsia (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
24. Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.
25. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 2006;119:198-202.
26. Gallivan S, Robson SC, Chang TC, Vaughan J, Spencer JA. An investigation of fetal growth using serial ultrasound data. Ultrasound Obstet Gynecol 1993;3:109-14.
27. Papageorghiou AT, Yu CK, Nicolaides KH. The role of uterine artery Doppler in predicting adverse pregnancy outcome. Best Pract Res Clin Obstet Gynaecol 2004;18:383-96.
28. McParland P, Pearce JM, Chamberlain GV. Doppler ultrasound and aspirin in recognition and prevention of pregnancy-induced hypertension. Lancet 1990;335:1552-5.
29. Bower SJ, Harrington KF, Schuchter K, McGirr C, Campbell S. Prediction of pre-eclampsia by abnormal uterine Doppler ultrasound and modification by aspirin. Br J Obstet Gynaecol 1996;103:625-9.
30. Morris JM, Fay RA, Ellwood DA, Cook CM, Devonald KJ. A randomized controlled trial of aspirin in patients with abnormal uterine artery blood flow. Obstet Gynecol 1996;87:74-8.
31. Zimmerman P, Eiriö V, Koskinen J, Niemi K, Nyman R, Kujansuu E, Ranta T. Effect of low-dose aspirin treatment on vascular resistance in the uterine, uteroplacental, renal and umbilical arteries - a prospective longitudinal study on a high risk population with persistent notch in the uterine arteries. Eur J Ultrasound 1997;5:17-30.
32. Harrington K, Kurdi W, Aquilina J, England P, Campbell S. A prospective management study of slow-release aspirin in the palliation of uteroplacental insufficiency predicted by uterine artery Doppler at 20 weeks. Ultrasound Obstet Gynecol 2000;15:13-8.
33. Vainio M, Kujansuu E, Iso-Mustajärvi M, Maenpää J. Low dose acetylsalicylic acid in prevention of pregnancy-induced hypertension and intrauterine growth retardation in women with bilateral uterine artery notches. BJOG 2002;109:161-7.
34. Subtil D, Goeusse P, Houfflin-Debarge V, Puech F, Lequien P, Breart G, et al. Randomised comparison of uterine artery Doppler and aspirin (100 mg) with placebo in nulliparous women: the Essai Regional Aspirine Mere-Enfant study (part 2). BJOG 2003;110:485-91.
35. Yu CK, Parpageorghiou AT, Parra M, Palma Dias R, Nicholaides KH. Randomized controlled trial using low-dose aspirin in the prevention of pre-eclampsia in women with abnormal uterine artery Doppler at 23 weeks' gestation. Ultrasound Obstet Gynecol 2003;22:233-9.
36. Ebrashy A, Ibrahim M, Marzook A, Yousef D. Usefulness of aspirin therapy in high-risk pregnant women with abnormal uterine artery Doppler ultrasound at 14-16 weeks pregnancy: randomized controlled clinical trial. Croat Med J 2005;46:826-31.
37. Alfirevich Z, Neilson JP. Doppler ultrasonography in high-risk pregnancies: systematic review with meta-analysis. Am J Obstet Gynecol 1995;172:1379-87.
38. Howley HEA, Walker M, Rodger MA. A systematic review of the association between factor V Leiden or prothrombin gene variant and intrauterine growth restriction. Am J Obstet Gynecol 2005;192:694-708.
39. Infante-Rivard C, Rivard GE, Yotov WV, Genin E, Guiguet M, Weinberg C, et al. Absence of association of thrombophilia polymorphism with intrauterine growth restriction. N Engl J Med 2002;347:19-25.
40. Dizon-Townsend D, Miller C, Sibai B, Spong CY, Thom E, Wendel G, et al. The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol 2005;106:517-24.
41. Lindqvist PG, Svensson PJ, Marsal K, Grennert L, Luterkort M, Dahlbäck B. Activated protein c resistance (FVQ506) and pregnancy. Thromb Haemost 1999;81:532-7.
42. Murphy RP, Donoghue R, Nallen R, D'Mello M, Regan C, Whitehead AS. Prospective evaluation of the risk conferred by factor V Leiden and thermolabile methylenetetrahydrofolate reductase polymorphisms in pregnancy. Arterioscler Thromb Vasc Biol 2000;20:266-70.
43. Airoldi J. Inherited thrombophilia. In: Berghella V, editor. Maternal-fetal evidence based guidelines. New York (NY): Informa Healthcare; 2007.
44. Gibson CS, MacLennan AH, Janssen NG, Kist WJ, Hague WM, Haan EA, et al. Associations between fetal inherited thrombophilia and adverse pregnancy outcomes. Am J Obstet Gynecol 2006;194:947-53.
45. Garner P, Gulmezoglu AM. Drugs for preventing malaria in pregnant women (Cochrane Review). In: The Cochrane Library, Issue 4, 2006. Oxford: Update Software.